Skip to main content
Medical information Clinical review pending

Genetic Testing

COL5A2 Gene Ehlers-Danlos Syndrome Type 12 Genetic Test

Genetic test analyzing the COL5A2 gene to help diagnose Ehlers-Danlos Syndrome Type 12, a connective tissue disorder. Uses Next-Generation Sequencing (NGS) technology.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube), Extracted DNA, or One Drop of Blood on FTA Card.
Results
3 to 4 Weeks. Confirm with the laboratory before booking.
Preparation
A clinical history of the patient is required. A genetic counseling session to draw a pedigree chart of affected family members is recommended before testing. Confirm with the laboratory before booking.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the COL5A2 Gene Ehlers-Danlos Syndrome Type 12 Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Symptoms suggestive of Ehlers-Danlos Syndrome (e.g., joint hypermobility, skin fragility, easy bruising).
  • ✓Family history of Ehlers-Danlos Syndrome or related connective tissue disorders.
  • ✓Referral from a specialist (e.g., geneticist, dermatologist) for evaluation of a connective tissue disorder.
  • ✓Confirmation of diagnosis in individuals with suspected EDS Type 12.
02

In plain language

What this test helps you understand

This test helps identify mutations in the COL5A2 gene associated with Ehlers-Danlos Syndrome Type 12, aiding in diagnosis and genetic counseling.
The COL5A2 Gene Ehlers-Danlos Syndrome Type 12 NGS Genetic DNA Test is designed to identify mutations in the COL5A2 gene. This gene provides instructions for making a specific type of collagen, a protein essential for the structure and strength of connective tissues throughout the body. This test is used to help diagnose Ehlers-Danlos Syndrome (EDS) Type 12, a rare inherited disorder affecting connective tissues. EDS can cause symptoms like joint hypermobility, fragile skin, easy bruising, and chronic pain.

This test utilizes Next-Generation Sequencing (NGS) technology to analyze the COL5A2 gene in a DNA sample. NGS allows for a detailed examination of the gene's sequence to detect specific changes (mutations) that may be responsible for the condition.

Understanding the results of this test can help individuals and their families understand the cause of their symptoms, make informed decisions about management and treatment, and assess the risk for other family members.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationA clinical history of the patient is required. A genetic counseling session to draw a pedigree chart of affected family members is recommended before testing. Confirm with the laboratory before booking.
SampleBlood sample (EDTA tube), Extracted DNA, or One Drop of Blood on FTA Card.
MethodologyNext-Generation Sequencing (NGS) of the COL5A2 gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test specifically analyzes the COL5A2 gene. It does not detect mutations in other genes associated with different types of Ehlers-Danlos Syndrome or other connective tissue disorders. A negative result does not completely rule out EDS, as other genetic causes may be involved. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

EDS Type 12 is a rare inherited disorder affecting connective tissues, caused by mutations in the COL5A2 gene. It can lead to symptoms like joint hypermobility, skin fragility, and easy bruising.
The test analyzes a DNA sample (usually from blood) to look for specific mutations in the COL5A2 gene using Next-Generation Sequencing (NGS) technology.
Individuals with symptoms suggestive of EDS Type 12, or those with a family history of the condition, should discuss this test with their doctor.
Results should be discussed with a healthcare provider or genetic counselor who can explain the findings in the context of your medical history and family information.
Yes, genetic counseling is highly recommended before and after testing to understand the implications of the results and discuss family planning.
A blood sample, extracted DNA, or a single drop of blood on an FTA card can be used. Please confirm the specific requirement with the laboratory.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp